SCHEMBL10189459

SCHEMBL10189459

COc1ccc(-c2csnc2-c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)C(N)CCC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CIT O14578 1/20 0.37
RXFP1 Q9HBX9 1/20 0.36
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
PRNP P04156 2/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ADAMTS4 O75173 2/20 0.35
ADAMTS5 Q9UNA0 2/20 0.35
CASR P41180 1/20 0.35
POLB P06746 1/20 0.35
TNF P01375 1/20 0.35
NOD2 Q9HC29 1/20 0.35
NOD1 Q9Y239 1/20 0.35
GPR142 Q7Z601 1/20 0.35
S1PR1 P21453 1/20 0.35
AAK1 Q2M2I8 2/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADORA2B P29275 1/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10240329 1.00 CIT (0.37) CITRXFP1MEN1KMT2APRNP
SCHEMBL10242420 1.00 CIT (0.37) CITRXFP1MEN1KMT2APRNP
Hydrochloric Acid SCHEMBL616864 0.99 CIT (0.37) CITRXFP1MEN1KMT2APRNP
SCHEMBL10189429 0.95 S1PR1 (0.38) CITRXFP1MEN1KMT2APRNP
SCHEMBL10189427 0.95 S1PR1 (0.38) CITRXFP1MEN1KMT2APRNP
SCHEMBL10241729 0.93 CIT (0.37) CITRXFP1MEN1KMT2APOLB
SCHEMBL10241279 0.93 CIT (0.37) CITRXFP1MEN1KMT2APOLB
Hydrochloric Acid SCHEMBL621174 0.92 CIT (0.37) CITRXFP1MEN1KMT2APOLB
SCHEMBL10242411 0.91 CIT (0.40) CITRXFP1MEN1KMT2ACASR
SCHEMBL10241284 0.91 CIT (0.40) CITRXFP1MEN1KMT2ACASR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN (US) 2013-08-08 US disclosed
US-8399435-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-03-19 US disclosed
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-02-16 US disclosed
US-8058297-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2011-11-15 US disclosed
US-20090270353-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN 2009-10-29 US disclosed
US-7572821-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2009-08-11 US disclosed
US-20070179159-A1 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179159-A1 Compounds for the treatment of proliferative disorders RB1, MKI67, MAPRE1 CIT 337/4885RXFP1 847/4885MEN1 1571/4885
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 CIT 337/4885RXFP1 847/4885MEN1 1571/4885
US-20090270353-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 CIT 337/4885RXFP1 847/4885MEN1 1571/4885
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 CIT 337/4885RXFP1 847/4885MEN1 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.